Department of Developmental Neurology, Poznan University of Medical Sciences, Poznań, Poland.
Department of Developmental Neurology, Poznan University of Medical Sciences, Poznań, Poland.
Pharmacol Rep. 2014 Dec;66(6):972-5. doi: 10.1016/j.pharep.2014.06.005. Epub 2014 Jun 21.
The aim of the study was the comparison of concentrations of IL-1β, IL-2, IL-6 and TNFα before and after valproate (VPA) treatment in blood serum in patients with generalized seizures diagnosed and treated in the Department of Developmental Neurology, Poznan University of Medical Sciences from January 2006 to May 2007.
The analysis was conducted in a group of 21 patients with well controlled, generalized seizures (mean age 7.7±4.7 years) before and after 4-6 months of VPA therapy. Quantitative determination IL-1β, IL-2, IL-6 and TNFα were performed with method of enzyme-linked immunosorbent assay (ELISA). The serum drug concentration was determined with the use of fluorescence-polarization-immunoassay system (FPIA).
The concentration of IL-6 in blood serum of patients decreased significantly (p<0.001) after 4-6 months of VPA therapy, but concentration of IL-1β (p=0.732), IL-2 (p=0.865), TNFα (p=0.079) did not change significantly. The serum concentration of VPA in all of patients was in therapeutic range (mean 77.53±19.71μg/ml).
The serum level of pro-inflammatory IL-6 in patients with generalized epilepsy decreased in statistically significant way during VPA therapy, so the anti-inflammatory properties of VPA are also important for the effective control of seizure. Due to the incompatibility of reports on the influence of VPA on cytokine system in patients with generalized epilepsy, this problem needs more investigations, especially in the group of children.
本研究旨在比较在 2006 年 1 月至 2007 年 5 月期间于波兹南医科大学发展神经学系确诊并治疗的全身性癫痫患者,在接受丙戊酸钠(VPA)治疗前后血清中白细胞介素-1β(IL-1β)、白细胞介素-2(IL-2)、白细胞介素-6(IL-6)和肿瘤坏死因子-α(TNFα)的浓度。
该分析纳入了 21 例经 VPA 治疗 4-6 个月后病情得到良好控制的全身性癫痫患者(平均年龄 7.7±4.7 岁)。采用酶联免疫吸附试验(ELISA)法测定 IL-1β、IL-2、IL-6 和 TNFα 的定量,采用荧光偏振免疫分析系统(FPIA)测定血清药物浓度。
VPA 治疗 4-6 个月后,患者血清中 IL-6 浓度显著降低(p<0.001),但 IL-1β(p=0.732)、IL-2(p=0.865)、TNFα(p=0.079)浓度无显著变化。所有患者的血清 VPA 浓度均在治疗范围内(平均 77.53±19.71μg/ml)。
在 VPA 治疗期间,全身性癫痫患者的促炎细胞因子 IL-6 血清水平呈显著下降趋势,因此 VPA 的抗炎特性对于有效控制癫痫发作也很重要。由于关于 VPA 对全身性癫痫患者细胞因子系统影响的报告不一致,因此需要进一步研究,尤其是在儿童群体中。